TreverGBivonaMD
Oncology • San Francisco, CAAssistant Professor, Medicine, University of California, San Francisco, School of Medicine
Dr. Bivona is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1600 Divisadero Street 4th floor
Box 1674
San Francisco, CA 94115Phone+1 415-353-7160
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2007 - 2011
Brigham and Women's HospitalResidency, Internal Medicine, 2005 - 2007
New York University School of MedicineClass of 2005
Certifications & Licensure
CA State Medical License 2012 - 2025
NY State Medical License 2007 - 2012
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Publications & Presentations
PubMed
- 1811 citationsOncogenic Signaling Pathways in The Cancer Genome AtlasFrancisco Sanchez-Vega, Marco Mina, Joshua Armenia, Walid K. Chatila, Augustin Luna
Cell. 2018-04-05 - 132 citationsA framework for understanding and targeting residual disease in oncogene-driven solid cancersTrever G. Bivona, Robert C. Doebele
Nature Medicine. 2016-05-01 - 8 citationsFocal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer.Franziska Haderk, Yu-Ting Chou, Lauren Cech, Celia Fernández-Méndez, Johnny Yu
Nature Communications. 2024-05-03
Journal Articles
- Aurora Kinase A Drives the Evolution of Resistance to Third-Generation EGFR Inhibitors in Lung CancerVictoria E Wang, Collin M Blakely, Trever G Bivona, Andrei Goga, Nature
- Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient with a MET Exon 14 Skipping MutationJulia K Rotow, Trever G Bivona, Collin M Blakely, Clinical Lung Cancer
- RAS Nucleotide Cycling Underlies the SHP2 Phosphatase Dependence of Mutant BRAF-, NF1- and RAS-Driven CancersTrever Bivona, MD, Nature
Authored Content
- Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient with a MET Exon 14 Skipping MutationNovember 2018
Press Mentions
Damon Runyon Cancer Research Foundation Awards over $4.1 Million to Exceptional Early-Career ScientistsJuly 28th, 2022- Damon Runyon Cancer Research Foundation Awards $4.8 Million to Rising InvestigatorsJuly 15th, 2021
- Novel Structure Found in Tumor Cells May Open Door to New Kinds of Cancer TherapiesMay 11th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
